Three Healthcare Stocks With Compelling Dividend Yields And Growth Rates

Published Wed, 16 Apr 2014 23:00 CET by DividendYields.org

The healthcare sector offers one of the best opportunities for investors. This is because health is not a luxury, and for some people it is a constant expense in their budgets.
Over the years, several companies have joined the market in different capacities and with various distinct target markets. While biotechnology companies are considered high reward speculative opportunities, large drug manufacturers like U.S.A’s Johnson & Johnson (NYSE: JNJ) and U.K’s GlaxoSmithKline (NYSE: GSK) offer stability and continuous payout in terms of dividends.
Over the last few years these two, along with Baxter International (NYSE: BAX), have shown resilience in their quest to grow dividends and maintain compelling yields. Now, these three form some of the most attractive dividend stocks in the healthcare sector.

Div Yield Div Growth (5 Yrs) Payout Ratio Exp Earnings Growth (1 yr) Exp Earnings Growth (5 yrs)
Johnson & Johnson 2.66% 7.49% 54% 7.72% 5.96%
GlaxoSmithKline 5.73% 4.23% 66% 9.26% 9.30%
Baxter International 2.67% 15.47% 52% 6.80% 7.45%
Johnson & Johnson
The U.S-based drug manufacturer offers investors a 2.66% dividend yield, based on its current stock price of $99.20 per share. This is after cruising 22.39% over the last 12 months.
Johnson & Johnson enjoys a wide economic moat, is well diversified and offers several products related to human health and hygiene. This provides the stability needed for dividend stocks, to prevent earnings and dividends from falling massively when one business segment performs poorly.
The company’s payout ratio of 54% is within the recommended threshold of not more than 60%, which means there is enough margin of safety to maintain a healthy dividend.
Johnson & Johnson earnings are expected to grow by 7.72% over the next 12 months, and at a compound annual growth rate “CAGR” of 5.96% over the next five years. In this case, the company’s expected 7.49% dividend growth rate for the next five years implies that, at some point, it might have to increase the payout ratio.

GlaxoSmithKline
GlaxoSmithKline is probably the most attractive dividend stock in the healthcare sector. The company offers compelling dividend yield of 5.73% and almost unmatched earnings growth rates for the next five years at 9.30%. Based on these figures, the company’s dividend yield is expected to grow by 4.23%.
GlaxoSmithKline earnings per share are expected to grow by 9.26% for the next one year.
Now, based on the company’s projected dividend growth rate compared to earnings growth rate, it appears as though the payout ratio could be cut significantly. This is positive for the company as it currently pays out 66% of its earnings as dividend, which is slightly above the recommended maximum rate.
Unlike Johnson & Johnson, GlaxoSmithKline’s price is only up about 5.95% over the last twelve months. However, its huge dividend yield has been a terrific example of how dividend stocks could differ from income stocks.

Baxter International
This is the smallest of the three healthcare giants. However, its market cap of more than $40 billion makes it a giant in its own respect. Therefore, it offers significant financial stability to investors.
When compared with is counterparts, Baxter International offers the best option for investors looking to reap more in term of dividends over the next five years. Its dividend is expected to grow by an average of 15.47% over the next five years. This means that the current quarterly dividend per share of $0.49 could rise to $0.56 next year.
The company’s payout ratio of 52% is also the best among the three companies. Baxter International operates in a slightly different industry from its two counterparts.
The medical instruments and supplies provider is also expected to enjoy significant earnings growth over the next five years at about 7.45% CAGR, which again is a clear signal for sustainable dividend payments.

Conclusion

12-Month Stock Price Graph
While GlaxoSmithKline offers the best dividend yield at current prices, Baxter International appears to be a compelling candidate for that tag in the coming years.
On the other hand, Johnson & Johnson enjoys wide economic moat and the best 12-month returns for those who might consider offloading some holding for cash, compared to GlaxoSmithKline’s 5.95%, and Baxter’s 3.47%.
Overall, they all appear to be some excellent dividend stocks to consider in 2014.


Stock name Dividend Yield
Glaxosmithkline 4.64
Johnson & Johnson 2.45
Baxter International 1.13

Articles featuring Glaxosmithkline (GSK):

5%+ Dividend Yield Portfolio: Profiting From A Return To Normal (October 2018 Review)

Outlook Volatility has returned to the markets. By this I don’t mean the big dig from the recent price highs... I am referring to the "normal" week-to-week and month-to-month gyrations that have are closer to the historical trends than the quiet uptrend that has mostly defined the past 10 months. However, this has been a stock picker's market, where the market gives and takes in strong moves in either direction. Momentum stocks (especially large-cap tech) have broken... Read more

Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November

Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They are tinted gray in the chart above). Thus, this yield-based forecast for Healthcare WallStars as graded by Wall St. proved 50% accurate. Projections based on estimated dividend amounts from $1000... Read more

Bert's October Dividend Income Summary

Another month. The leaves are changing, Halloween is behind us, and I have officially eaten way too much Halloween candy! My wife and I love the fall season, and even had a chance to go apple picking before the weather was too cold and make some fantastic desserts with our haul. But that's not the point of this article, is it? Each month, we like to summarize our results and check out the growth and progress we are making in terms of dividend income. Lanny kicked off the festivities by... Read more

5%+ Dividend Yield Portfolio: Playing Offense, Not Running Scared (October 2018 Review)

Outlook ‘Well that was unpleasant,’ says basically any market participant of October 2018. With all major markets in/flirting with correction territory, there was no place to hide from a decline. However, not all declines were of equal magnitude as a 2X4 was taken to the formerly high-flying tech stocks but defensive stocks and REITs performed much better. October 2018 was an opportunity for my portfolio to shine as my holdings only fell -4.1% versus the -7.8% for the... Read more

5%+ Dividend Yield Portfolio: Ignore The Political Circus (Sep 2018 Review)

Outlook If you mix your politics with your investment decisions, you’re making a big mistake. - Warren Buffett Politics dominates the headlines these days (even in the financial press)… and how could it not with the circus on display. However, allowing your political views to shade your investment decisions is a sure loser. In fact, even following the political headlines too closely, even when they touch on the economy (e.g. the many threatened or real government shutdowns... Read more